More promising results, however, were announced the same month by Eli Lilly for its new once-daily GLP-1 pill which showed promise for weight management and for the treatment of type-2 diabetes
Cancer Risk Among People With Type 1 and Type 2 Diabetes: Disentangling True Associations, Detection Bias, and Reverse Causation
Review bloodwork, assess side effects, discuss dose optimization, and evaluate progress against expectations
Compelling evidence from landmark clinical trials, particularly STEP-HFpEF, STEP-HFpEF DM and SUMMIT, has established the efficacy of GLP-1RAs in improving HF-related symptoms and quality of life, as well as reducing worsening HF events, in the prevalent phenotype of HFpEF in the setting of obesity and T2D
Seek clinics dedicated to providing ongoing support beyond the prescription
Chemosensory properties of the trigeminal system